Licensing opportunities

Wherever possible protect our intellectual property through patents in collaboration with Cancer Research Technology or University College London Business. All of our markers are available for licensing and we are always interested in working with commercial partners to further develop our biomarkers for clinical use and patient benefit.

Prognostic prostate cancer biomarkers

Radical prostatectomy is the recommended treatment for aggressive prostate cancer and 45% of US patients presenting with the disease will ultimately receive this treatment. Post-surgery, patients face a difficult decision based on their risk of recurrence to either receive adjuvant therapy with associated toxicities or opt for active surveillance. Current markers, such as PSA and gleason grade, used to determine risk are sub-optimal and there is a high unmet clinical need to better define risk of recurrence in the post-prostatectomy patient population. Two novel prognostic biomarkers have been identified and shown to be independent of gleason grade and PSA; when these are combined with current clinical practice these markers could help better predict the risk of recurrence and enable more informed adjuvant therapy decision making. Further details are available here.

A diagnostic biomarker for pancreatic cancer and cholangiocarcinoma

Patients with suspected pancreatic cancer will undergo an initial CT scan to determine if a suspect mass is localized and resectable. However, 63% of patients will be diagnosed with non-resectable stage III and IV disease and a biopsy will be undertaken to confirm pancreatic cancer by H&E pathological analysis. Confirming the presence of cancerous cells via pathology is very challenging due to high numbers of non-cancerous stromal infiltrating cells and administration of chemotherapy or enrolment into a clinical trial will only commence on definitive diagnosis of pancreatic cancer by H&E. A marker which only specifically stains neoplastic pancreatic cells would enable the pathologist to confidently diagnose pancreatic cancer and thus offer appropriate cancer treatment to the patients. BI-010 has been identified as a highly sensitive (98%) and specific (95%) IHC marker for pancreatic cancer and CRT is seeking a partner to develop an IHC based test to detect BI-010 in fine needle aspirate biopsies from biopsy samples. Further details are available here.